Press Releases

Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117570 in healthy adult participants. NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist that may have the potential to treat neurological and neuropsychiatric conditions. "Initiation of this Phase 1 study represents an i

The first part of the influential CPHI Annual Report predicts sizeable progress ahead for AI’s use in pharma, as despite the wider excitement around ChatGPT and other generative AI’s having cooled in recent months, pharma’s real-world applications continue to expand. The implications go far beyond its current use and most startling of all – notwithstanding the so far limited successes – it is expected that within 10-years over 50% of approved drugs will involve A

Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai. With the aim of relieving the anxieties of people with dementia and their families and addressing social issues, Eisai is not only creating therapeutic drugs, but also working to build a dementia ecosystem through t

Genialis, the RNA-biomarker company, today announced the addition of several new team members as the company works to improve healthcare and deliver the best possible outcomes for patients, their families and communities. Among the new additions are Aditya Pai, head of business development, who spent over a decade at IBM scaling Watson for Genomics; and Mark Uhlik, who joins as the new head of biomarker development after serving as head of research and biomarker discovery at OncXerna, with pr

Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that the US Food and Drug Administration's Office of Orphan Products Development has granted orphan-drug designation for the treatment of soft tissue sarcoma (ST

The Aesthetic and Anti-Aging Medicine World Congress (AMWC) is set to make a remarkable debut in India with AMWC India 2023, presented through a collaboration between Informa Medical Aesthetics (IM-aesthetics), a global leader in medical aesthetics events, and Informa Markets in India. Scheduled for September 15–16, 2023, at the prestigious Hotel Sahara Star in Mumbai. AMWC India 2023 aims to bring together industry experts, renowned speakers, and an expansive exhibit area covering over

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems. "Our goal is to make sample and library preparation easier for our customers," said Jeff Eidel, Chief Commercial Officer at PacBio. "These automated library preparation solutions are

Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, announces a strategic collaboration with BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions. The collaboration aims to lever

Manufacturers in the field of pharma and nutraceuticals can step into a new era of uncomplicated and future-proof formulation: With the Omyanutra® range, Suisse mineral expert Omya offers advanced excipients to overcome the challenge of producing stable and fast disintegrating oral tablets (ODTs) and powders. The raw material is sourced from the company´s high-purity minerals and treated with patented technology. Thus, the natural mineral particles gain a new porous and lamellar str

Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies. The multi-year partnership will leverage Gustave Roussy’s expansive biorepository of tumor samples a